Dermatologic manifestations of cytotoxic therapy

Dermatologic Therapy

Volumn 24, Issue 4, 2011, Pages 401-410

  Huang, Victor ^a   Anadkat, Milan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adverse effects; cutaneous; cytotoxic

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; EDATREXATE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; LIDOCAINE; MELPHALAN; MERCAPTOPURINE; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; SUCRALFATE; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACTINIC KERATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANAGEN EFFLUVIUM; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; DRUG BLOOD LEVEL; DRUG DNA BINDING; DRUG DOSE COMPARISON; DRUG EXTRAVASATION; DRUG HYPERSENSITIVITY; DRUG TISSUE LEVEL; ECCRINE SQUAMOUS SYRINGOMETAPLASIA; ERYTHEMA; HAND FOOT SYNDROME; HIDRADENITIS; HUMAN; HYPERPIGMENTATION; LOW LEVEL LASER THERAPY; METAPLASIA; MUCOSA INFLAMMATION; NAIL DYSTROPHY; NEUTROPHIL ECCRINE HIDRADENITIS; NEUTROPHILIC ECCRINE HIDRADENITIS; PHOTOTHERAPY; PHOTOTOXICITY; RADIATIN RECALL; RADIATION EXPOSURE; RADIATION INJURY; RADIOSENSITIVITY; REVIEW; SERPENTINE SUPRAVENOUS HYPERPIGMENTATION; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS;

ANTINEOPLASTIC AGENTS; DNA REPLICATION; DRUG ERUPTIONS; HUMANS; NEOPLASMS;

EID: 80052764928     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2011.01432.x     Document Type: Review

References (84)

1. Hirsch J,. An anniversary for cancer chemotherapy. JAMA 2006: 296 (12): 1518-1520. (Pubitemid 44465516)
2. Keefe DM, Schubert MM, Elting LS, et al,. Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007: 109 (5): 820-831. (Pubitemid 46335677)
3. Sonis ST, Elting LS, Keefe D, et al,. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer, International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004: 100 (9 Suppl.): 1995-2025. (Pubitemid 38528741)
4. Shieh SH, Wang ST, Tsai ST, Tseng CC,. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncol 1997: 33 (1): 36-41.
5. Chiara S, Nobile T, Vincenti M, et al,. Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study. Anticancer Res 2001: 21 (5): 3707-3710. (Pubitemid 34224289)
6. McGinnis WL, Loprinzi CL, Buskirk SJ, et al,. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol 1997: 15 (3): 1239-1243. (Pubitemid 27106312)
7. Loprinzi CL, Ghosh C, Camoriano J, et al,. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol 1997: 15 (3): 1235-1238. (Pubitemid 27106311)
8. Carafate [package insert]. Birmingham, AL: Axcan Pharma US, Inc.; 2007.
9. Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S,. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 2008: 112 (7): 1600-1606. (Pubitemid 351441174)
10. Svanberg A, Ohrn K, Birgegard G,. Oral cryotherapy reduces mucositis and improves nutrition-a randomised controlled trial. J Clin Nurs 2010: 19 (15-16): 2146-2151.
11. Gouvea de Lima A, Villar RC, de Castro G Jr, et al,. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study. Int J Radiat Oncol Biol Phys 2010: [ePub ahead of print December 14, 2010].
12. Silva GB, Mendonca EF, Bariani C, Antunes HS, Silva MA,. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg 2011: 29 (1): 27-31.
13. Schubert MM, Eduardo FP, Guthrie KA, et al,. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 2007: 15 (10): 1145-1154. (Pubitemid 47459866)
14. Panahi Y, Ala S, Saeedi M, Okhovatian A, Bazzaz N, Naghizadeh MM,. Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis. Eur J Cancer Care (Engl) 2010: 19 (3): 308-312.
15. Porta C, Moroni M, Nastasi G,. Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol 1994: 17 (3): 246-247. (Pubitemid 24160618)
16. Brizel DM, Murphy BA, Rosenthal DI, et al,. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008: 26 (15): 2489-2496.
17. Rosen LS, Abdi E, Davis ID, et al,. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006: 24 (33): 5194-5200. (Pubitemid 46631362)
18. Lemieux J, Maunsell E, Provencher L,. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 2008: 17 (4): 317-328. (Pubitemid 351513680)
19. Perez-Crespo M, Betlloch I, Ballester I, Lucas A, Mataix J, Niveiro M,. Irreversible alopecia due to busulphan in a 7-year-old girl. Eur J Dermatol 2009: 19 (2): 192-193.
20. Machado M, Moreb JS, Khan SA,. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant 2007: 40 (10): 979-982. (Pubitemid 350048197)
21. de Jonge ME, Mathot RA, Dalesio O, Huitema AD, Rodenhuis S, Beijnen JH,. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant 2002: 30 (9): 593-597. (Pubitemid 35414809)
22. Vassallo C, Brazzelli V, Ardigo M, Borroni G,. The irreplaceable image: nails changes in onco-hematologic patients. Haematologica 2001: 86 (3): 334-336. (Pubitemid 32291082)
23. Gilbar P, Hain A, Peereboom VM,. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 2009: 15 (3): 143-155.
24. Flory SM, Solimando DA Jr, Webster GF, Dunton CJ, Neufeld JM, Haffey MB,. Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother 1999: 33 (5): 584-586. (Pubitemid 29255069)
25. Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS,. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 2000: 88 (10): 2367-2371. (Pubitemid 30247138)
26. Sliesoraitis S, Chikhale PJ,. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005: 15 (1): 13-18. (Pubitemid 40194327)
27. Raetz EA, Salzer WL,. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010: 32 (7): 554-563.
28. Rowinsky EK, Donehower RC,. Paclitaxel (taxol). N Engl J Med 1995: 332 (15): 1004-1014.
29. Moon C, Verschraegen CF, Bevers M, Freedman R, Kudelka AP, Kavanagh JJ,. Use of docetaxel (taxotere) in patients with paclitaxel (taxol) hypersensitivity. Anticancer Drugs 2000: 11 (7): 565-568.
30. Taxol (paclitaxel) injection [package insert]. Ben Venue Laboratories, Inc.: Bedford, OH; 2010.
31. O'Dwyer PJ, King SA, Fortner CL, Leyland-Jones B,. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol 1986: 4 (8): 1262-1269. (Pubitemid 16043878)
32. Kellie SJ, Crist WM, Pui CH, et al,. Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia. Cancer 1991: 67 (4): 1070-1075.
33. Brooks BJ Jr, Hendler NB, Alvarez S, Ancalmo N, Grinton SF,. Delayed life-threatening pneumonitis secondary to procarbazine. Am J Clin Oncol 1990: 13 (3): 244-246. (Pubitemid 20247669)
34. Mahmood T, Mudad R,. Pulmonary toxicity secondary to procarbazine. Am J Clin Oncol 2002: 25 (2): 187-188. (Pubitemid 34293076)
35. Castells M,. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol 2006: 6 (4): 271-277. (Pubitemid 44510183)
36. Lee C, Gianos M, Klaustermeyer WB,. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009: 102 (3): 179-187; quiz 187-189, 222.
37. Shepherd GM,. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003: 24 (3): 253-262. (Pubitemid 36584220)
38. Weiss RB,. Hypersensitivity reactions. Semin Oncol 1992: 19 (5): 458-477.
39. Pagani M,. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 2010: 94 (4): 835-852; xiii.
40. Langer SW,. Extravasation of chemotherapy. Curr Oncol Rep 2010: 12 (4): 242-246.
41. Schulmeister L,. Extravasation management. Semin Oncol Nurs 2007: 23 (3): 184-190.
42. Schulmeister L,. Extravasation management: clinical update. Semin Oncol Nurs 2011: 27 (1): 82-90.
43. Sauerland C, Engelking C, Wickham R, Corbi D,. Vesicant extravasation part I: mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006: 33 (6): 1134-1141.
44. Wickham R, Engelking C, Sauerland C, Corbi D,. Vesicant extravasation part II: evidence-based management and continuing controversies. Oncol Nurs Forum 2006: 33 (6): 1143-1150.
45. Thougaard AV, Langer SW, Hainau B, et al,. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Toxicology 2010: 269 (1): 67-72.
46. Mouridsen HT, Langer SW, Buter J, et al,. Treatment of anthracycline extravasation with savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 2007: 18 (3): 546-550. (Pubitemid 46359637)
47. Ludwig CU, Stoll HR, Obrist R, Obrecht JP,. Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and alpha-tocopherole. Eur J Cancer Clin Oncol 1987: 23 (3): 327-329. (Pubitemid 17033682)
48. Bertelli G, Dini D, Forno GB, et al,. Hyaluronidase as an antidote to extravasation of vinca alkaloids: clinical results. J Cancer Res Clin Oncol 1994: 120 (8): 505-506. (Pubitemid 24205130)
49. Owen OE, Dellatorre DL, Van Scott EJ, Cohen MR,. Accidental intramuscular injection of mechlorethamine. Cancer 1980: 45 (8): 2225-2226. (Pubitemid 10150441)
50. Mizumoto M, Harada H, Asakura H, et al,. Frequency and characteristics of docetaxel-induced radiation recall phenomenon. Int J Radiat Oncol Biol Phys 2006: 66 (4): 1187-1191. (Pubitemid 44633500)
51. Tan CT, Dargeon HW, Burchenal JH,. The effect of actinomycin D on cancer in childhood. Pediatrics 1959: 24: 544-561.
52. Azria D, Magne N, Zouhair A, et al,. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005: 31 (7): 555-570. (Pubitemid 41614813)
53. Jeter MD, Janne PA, Brooks S, et al,. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002: 53 (2): 394-400. (Pubitemid 34525102)
54. Camidge R, Price A,. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001: 59 (3): 237-245. (Pubitemid 32429571)
55. Burris HA 3rd, Hurtig J,. Radiation recall with anticancer agents. Oncologist 2010: 15 (11): 1227-1237.
56. Burdon J, Bell R, Sullivan J, Henderson M,. Adriamycin-induced recall phenomenon 15 years after radiotherapy. JAMA 1978: 239 (10): 931. (Pubitemid 8288394)
57. Schwarte S, Wagner K, Karstens JH, Bremer M,. Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol 2007: 183 (4): 215-217. (Pubitemid 46570762)
58. Schweitzer VG, Juillard GJ, Bajada CL, Parker RG,. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995: 76 (6): 1069-1072.
59. Squire S, Chan M, Feller E, Mega A, Gold R,. An unusual case of gemcitabine-induced radiation recall. Am J Clin Oncol 2006: 29 (6): 636. (Pubitemid 44915303)
60. Borroni G, Vassallo C, Brazzelli V, et al,. Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma. Am J Dermatopathol 2004: 26 (3): 213-216. (Pubitemid 38669295)
61. Stein RS,. Radiation-recall enteritis after actinomycin-D and adriamycin therapy. South Med J 1978: 71 (8): 960-961. (Pubitemid 9024631)
62. Hird AE, Wilson J, Symons S, Sinclair E, Davis M, Chow E,. Radiation recall dermatitis: case report and review of the literature. Curr Oncol 2008: 15 (1): 53-62.
63. Lipworth AD, Robert C, Zhu AX,. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009: 77 (5): 257-271.
64. Bachmeyer C, Aractingi S,. Neutrophilic eccrine hidradenitis. Clin Dermatol 2000: 18 (3): 319-330. (Pubitemid 30336511)
65. Degen A, Alter M, Schenck F, et al,. The hand-foot-syndrome associated with medical tumor therapy-classification and management. J Dtsch Dermatol Ges 2010: 8 (9): 652-661.
66. Bolognia JL, Cooper DL, Glusac EJ,. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008: 59 (3): 524-529.
67. Lai SE, Kuzel T, Lacouture ME,. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007: 25 (3): 341-343.
68. Saif MW,. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 2010: 10 (2): 159-169.
69. Bachmeyer C, Chaibi P, Aractingi S,. Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor. Br J Dermatol 1998: 139 (2): 354-355. (Pubitemid 28389426)
70. Roustan G, Salas C, Cabrera R, Simon A,. Neutrophilic eccrine hidradenitis unassociated with chemotherapy in a patient with acute myelogenous leukemia. Int J Dermatol 2001: 40 (2): 144-147. (Pubitemid 32396566)
71. Yasukawa K, Kato N, Aikawa K, Kodama K, Hamasaka A, Hata H,. Neutrophilic eccrine hidradenitis with sclerodermoid change heralding the relapse of acute myelogenous leukemia: is this a paraneoplastic phenomenon? Dermatology 2007: 215 (3): 261-264. (Pubitemid 47378998)
72. Marcoux D, Anex R, Russo P,. Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine. J Am Acad Dermatol 2000: 43 (3): 540-546. (Pubitemid 30666752)
73. Geddes ER, Cohen PR,. Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy. South Med J 2010: 103 (3): 231-235.
74. Chen GY, Lee JY, Chen WC,. Sclerotic and retracted supravenous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma. Br J Dermatol 2005: 152 (6): 1383-1385. (Pubitemid 40933462)
75. Chittari K, Tagboto S, Tan BB,. Cyclophosphamide-induced nail discoloration and skin hyperpigmentation: a rare presentation. Clin Exp Dermatol 2009: 34 (3): 405-406.
76. Teresi ME, Murry DJ, Cornelius AS,. Ifosfamide-induced hyperpigmentation. Cancer 1993: 71 (9): 2873-2875. (Pubitemid 23120070)
77. Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ,. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 2008: 58 (4): 575-578.
78. Goldfeder KL, Levin JM, Katz KA, Clarke LE, Loren AW, James WD,. Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol 2007: 56 (3): 494-499. (Pubitemid 46273856)
79. Weger W, Kranke B, Gerger A, Salmhofer W, Aberer E,. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol 2008: 59 (2 Suppl. 1): S4-S6. (Pubitemid 351952412)
80. Floristan U, Feltes RA, Sendagorta E, et al,. Subacute cutaneous lupus erythematosus induced by capecitabine. Clin Exp Dermatol 2009: 34 (7): e328-e329.
81. Fernandes NF, Rosenbach M, Elenitsas R, Kist JM,. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy. Arch Dermatol 2009: 145 (3): 340-341.
82. English JC 3rd, Toney R, Patterson JW,. Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin. J Cutan Pathol 2003: 30 (9): 591-595. (Pubitemid 37255560)
83. Korver GE, Ronald H, Petersen MJ,. An intertrigo-like eruption from pegylated liposomal doxorubicin. J Drugs Dermatol 2006: 5 (9): 901-902.
84. Abess A, Keel DM, Graham BS,. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol 2003: 139 (3): 337-339. (Pubitemid 36330581)